Drugs / FHND6091
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05271682 | Dec 2021 → Dec 2023 | plasma cell myeloma | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FHND6091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05271682 ↗ |
| Route | Oral | “FHND6091, 0.4 mg, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period” NCT05271682 ↗ |